SCHEMBL30496613

SCHEMBL30496613

C#C[C@@]1(OC(=O)CCC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 8/20 0.67
▸ LMNA P02545 6/20 0.67
▸ AR P10275 6/20 0.67
▸ SLC6A4 P31645 5/20 0.67
▸ CYP3A4 P08684 5/20 0.67
▸ NR3C1 P04150 4/20 0.67
▸ ABCB11 O95342 4/20 0.67
▸ ESR1 P03372 4/20 0.67
▸ MEN1 O00255 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ CYP2C19 P33261 3/20 0.67
▸ SHBG P04278 3/20 0.67
▸ POLB P06746 1/20 0.67
▸ ADORA3 P0DMS8 2/20 0.66
▸ SLC6A2 P23975 2/20 0.66
▸ NR1I2 O75469 2/20 0.66
▸ AGTR1 P30556 1/20 0.66
▸ DRD3 P35462 1/20 0.66
▸ SLC6A3 Q01959 1/20 0.66
▸ PDE4D Q08499 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5078825 1.00 PGR (0.67) PGRLMNAARSLC6A4CYP3A4
SCHEMBL25863263 1.00 PGR (0.67) PGRLMNAARSLC6A4CYP3A4
SCHEMBL20927509 1.00 PGR (0.67) PGRLMNAARSLC6A4CYP3A4
SCHEMBL8853386 0.95 PGR (0.65) PGRLMNAARSLC6A4CYP3A4
SCHEMBL11694584 0.94 PGR (0.64) PGRLMNAARSLC6A4CYP3A4
SCHEMBL8853332 0.94 PGR (0.64) PGRLMNAARSLC6A4CYP3A4
SCHEMBL25863273 0.93 PGR (0.63) PGRLMNAARSLC6A4CYP3A4
SCHEMBL11694580 0.93 PGR (0.63) PGRLMNAARSLC6A4CYP3A4
SCHEMBL25863267 0.93 PGR (0.63) PGRLMNAARSLC6A4CYP3A4
SCHEMBL25863269 0.93 PGR (0.63) PGRLMNAARSLC6A4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3773730-B1 DRUG DELIVERY FORMULATIONS UNIV CALIFORNIA (US) 2026-05-13 — — EP claimed
EP-3773730-B1 DRUG DELIVERY FORMULATIONS UNIV CALIFORNIA (US) 2026-05-13 — — EP disclosed
US-20250041315-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-02-06 — — US disclosed
US-20250041315-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-02-06 — — US disclosed
EP-4447931-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-10-23 — — EP disclosed
EP-4447931-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-10-23 — — EP disclosed
EP-4447931-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-10-23 — — EP disclosed
CN-118488830-A Levonorgestrel butyrate formulations and methods relating thereto 美国政府(由卫生和人类服务部的部长所代表) 2024-08-13 — — CN disclosed
CN-118488830-A Levonorgestrel butyrate formulations and methods relating thereto 美国政府(由卫生和人类服务部的部长所代表) 2024-08-13 — — CN disclosed
WO-2023114205-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-06-22 — — WO disclosed
WO-2023114205-A1 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-06-22 — — WO disclosed
Send feedback